NCT03471897View on ClinicalTrials.gov

Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma

CompletedOBSERVATIONAL
Enrollment

237

Participants

Timeline

Start Date

April 28, 2016

Primary Completion Date

October 25, 2017

Study Completion Date

January 18, 2018

Conditions
Renal Cell Carcinoma
Interventions
DIAGNOSTIC_TEST

Glycosaminoglycan plasma score

A score was calculated using a formula that factors in measurements of plasma glycosaminoglycan. A score higher than a here-determined threshold is deemed diagnostic of RCC.

All Listed Sponsors
collaborator

Memorial Sloan Kettering Cancer Center

OTHER

lead

Chalmers University of Technology

OTHER

NCT03471897 - Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter